Company Description
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.
It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution.
It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies.
The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt.
As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
| Country | Israel |
| Founded | 1959 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,554 |
| CEO | Uday V. Baldota |
Contact Details
Address: 14 Haktor St Haifa Bay, L3 26110 | |
| Phone | 9143459001 |
| Website | taro.com |
Stock Details
| Ticker Symbol | TARO |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000906338 |
| CUSIP Number | M8737E108 |
| ISIN Number | IL0010827181 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Uday V. Baldota | Chief Executive Officer and Director |
| William J. Coote | Vice President, Chief Financial Officer and Chief Accounting Officer |
| Itamar Karsenti | Vice President and Head of Operations |
| Avi Avramoff | Vice President and Head of Research & Development |
| Itzik Baruch | Vice President of Technical Services |
| Dr. Roman Kaplan | Vice President of Scientific and Technical Compliance Manager |
| Erik Zwicker J.D. | Vice President, General Counsel and Secretary |
| Ara Aprahamian | Vice President of Sales and Marketing |
| Michele Visosky | Vice President and Head of Human Resource |
| Jayesh Shah | Head of Procurement |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 24, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Jun 24, 2024 | 6-K | Report of foreign issuer |
| Jun 24, 2024 | 25-NSE | Filing |
| May 23, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| May 23, 2024 | 6-K | Report of foreign issuer |
| May 21, 2024 | 6-K | Report of foreign issuer |
| May 14, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| May 8, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Apr 15, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |